10 assets in Biliary Tract Neoplasm

Therapeutic assets addressing Biliary Tract Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Fulvestrant Biliary Tract Neoplasm	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (53)
Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide Biliary Tract Neoplasm	Haihua Yuan	P2	CCC (53)
Nivolumab Biliary Tract Neoplasm	Instituto do Cancer do Estado de São Paulo	P2	CCC (53)
Trastuzumab Biliary Tract Neoplasm	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (53)
Tucatinib Biliary Tract Neoplasm	Seagen, a wholly owned subsidiary of Pfizer	P2	CCC (53)
Carboplatin Biliary Tract Neoplasm	Eli Lilly and Company	P1/2	CC (47)
Cetuximab Biliary Tract Neoplasm	Eli Lilly and Company	P1/2	CC (47)
Cis-Diamminedichloroplatinum Ii Biliary Tract Neoplasm	Eli Lilly and Company	P1/2	CC (47)
Olomorasib Biliary Tract Neoplasm	Eli Lilly and Company	P1/2	CC (47)
Pembrolizumab Biliary Tract Neoplasm	Eli Lilly and Company	P1/2	CC (47)